217 related articles for article (PubMed ID: 24183983)
1. The combination of GIP plus xenin-25 indirectly increases pancreatic polypeptide release in humans with and without type 2 diabetes mellitus.
Chowdhury S; Wang S; Patterson BW; Reeds DN; Wice BM
Regul Pept; 2013 Nov; 187():42-50. PubMed ID: 24183983
[TBL] [Abstract][Full Text] [Related]
2. Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance.
Wang S; Oestricker LZ; Wallendorf MJ; Sterl K; Dunai J; Kilpatrick CR; Patterson BW; Reeds DN; Wice BM
PLoS One; 2018; 13(2):e0192441. PubMed ID: 29466430
[TBL] [Abstract][Full Text] [Related]
3. Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes.
Chowdhury S; Reeds DN; Crimmins DL; Patterson BW; Laciny E; Wang S; Tran HD; Griest TA; Rometo DA; Dunai J; Wallendorf MJ; Ladenson JH; Polonsky KS; Wice BM
Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G301-9. PubMed ID: 24356886
[TBL] [Abstract][Full Text] [Related]
4. Metabolic responses to xenin-25 are altered in humans with Roux-en-Y gastric bypass surgery.
Sterl K; Wang S; Oestricker L; Wallendorf MJ; Patterson BW; Reeds DN; Wice BM
Peptides; 2016 Aug; 82():76-84. PubMed ID: 27288245
[TBL] [Abstract][Full Text] [Related]
5. Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes.
Wice BM; Reeds DN; Tran HD; Crimmins DL; Patterson BW; Dunai J; Wallendorf MJ; Ladenson JH; Villareal DT; Polonsky KS
Diabetes; 2012 Jul; 61(7):1793-800. PubMed ID: 22522617
[TBL] [Abstract][Full Text] [Related]
6. Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism.
Wice BM; Wang S; Crimmins DL; Diggs-Andrews KA; Althage MC; Ford EL; Tran H; Ohlendorf M; Griest TA; Wang Q; Fisher SJ; Ladenson JH; Polonsky KS
J Biol Chem; 2010 Jun; 285(26):19842-53. PubMed ID: 20421298
[TBL] [Abstract][Full Text] [Related]
7. Hormonal Responses to Cholinergic Input Are Different in Humans with and without Type 2 Diabetes Mellitus.
Chowdhury S; Wang S; Dunai J; Kilpatrick R; Oestricker LZ; Wallendorf MJ; Patterson BW; Reeds DN; Wice BM
PLoS One; 2016; 11(6):e0156852. PubMed ID: 27304975
[TBL] [Abstract][Full Text] [Related]
8. Xenin-25 increases cytosolic free calcium levels and acetylcholine release from a subset of myenteric neurons.
Zhang S; Hyrc K; Wang S; Wice BM
Am J Physiol Gastrointest Liver Physiol; 2012 Dec; 303(12):G1347-55. PubMed ID: 23086920
[TBL] [Abstract][Full Text] [Related]
9. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
[TBL] [Abstract][Full Text] [Related]
10. Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic Glu
Sarnobat D; Moffett RC; Gault VA; Tanday N; Reimann F; Gribble FM; Flatt PR; Irwin N
Peptides; 2020 Mar; 125():170205. PubMed ID: 31738969
[TBL] [Abstract][Full Text] [Related]
11. An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice.
Hasib A; Ng MT; Gault VA; Khan D; Parthsarathy V; Flatt PR; Irwin N
Diabetologia; 2017 Mar; 60(3):541-552. PubMed ID: 28004148
[TBL] [Abstract][Full Text] [Related]
12. Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Eur J Pharmacol; 2018 Sep; 834():126-135. PubMed ID: 30025814
[TBL] [Abstract][Full Text] [Related]
13. A GIP/xenin hybrid in combination with exendin-4 improves metabolic status in db/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice.
Craig SL; Perry RA; Vyavahare SS; Ng MT; Gault VA; Flatt PR; Irwin N
Biochem Pharmacol; 2020 Jan; 171():113723. PubMed ID: 31756326
[TBL] [Abstract][Full Text] [Related]
14. Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss.
Škrha J; Bušek P; Uhrová J; Hrabal P; Kmochová K; Laclav M; Bunganič B; Frič P
Pancreatology; 2017; 17(1):89-94. PubMed ID: 28027898
[TBL] [Abstract][Full Text] [Related]
15. GIP contributes to islet trihormonal abnormalities in type 2 diabetes.
Chia CW; Odetunde JO; Kim W; Carlson OD; Ferrucci L; Egan JM
J Clin Endocrinol Metab; 2014 Jul; 99(7):2477-85. PubMed ID: 24712564
[TBL] [Abstract][Full Text] [Related]
16. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats.
Lynn FC; Pamir N; Ng EH; McIntosh CH; Kieffer TJ; Pederson RA
Diabetes; 2001 May; 50(5):1004-11. PubMed ID: 11334402
[TBL] [Abstract][Full Text] [Related]
17. Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans.
Veedfald S; Vedtofte L; Skov-Jeppesen K; Deacon CF; Hartmann B; Vilsbøll T; Knop FK; Christensen MB; Holst JJ
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31665480
[TBL] [Abstract][Full Text] [Related]
18. Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man.
Ahrén B; Pettersson M; Uvnäs-Moberg K; Gutniak M; Efendic S
Diabetes Res Clin Pract; 1991 Sep; 13(3):153-61. PubMed ID: 1683622
[TBL] [Abstract][Full Text] [Related]
19. Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25.
Martin CM; Gault VA; McClean S; Flatt PR; Irwin N
Biochem Pharmacol; 2012 Aug; 84(3):312-9. PubMed ID: 22561048
[TBL] [Abstract][Full Text] [Related]
20. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
Elahi D; McAloon-Dyke M; Fukagawa NK; Meneilly GS; Sclater AL; Minaker KL; Habener JF; Andersen DK
Regul Pept; 1994 Apr; 51(1):63-74. PubMed ID: 8036284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
